{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=17",
    "query": {
      "condition": "Metastatic Skin Cancer",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 2838,
    "total_pages": 284,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T13:24:43.485Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06492759",
      "title": "High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2025-10-22",
      "completion_date": "2028-02-13",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06492759"
    },
    {
      "nct_id": "NCT02651610",
      "title": "Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Bavituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Taxane",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Peregrine Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2015-12",
      "completion_date": "2018-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 2,
      "location_summary": "Bakersfield, California • Tinley Park, Illinois",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Tinley Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02651610"
    },
    {
      "nct_id": "NCT03732560",
      "title": "A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Non-Interventional",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2018-07-31",
      "completion_date": "2021-03-25",
      "has_results": false,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 1,
      "location_summary": "Parsippany, New Jersey",
      "locations": [
        {
          "city": "Parsippany",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03732560"
    },
    {
      "nct_id": "NCT06264921",
      "title": "A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Metastatic Tumor",
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Ovarian Carcinoma",
        "Metastatic Ovarian Carcinoma",
        "Endometrial Cancer",
        "Endometrial Neoplasms",
        "Endometrial Diseases",
        "Metastatic Endometrial Cancer",
        "Metastatic Endometrial Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Ovarian Carcinoma",
        "Gastric Cancer",
        "Advanced Gastric Carcinoma",
        "Metastatic Gastric Cancer",
        "Metastatic Gastric Carcinoma",
        "Small-cell Lung Cancer",
        "Small Cell Lung Carcinoma",
        "Triple Negative Breast Cancer",
        "Triple Negative Breast Neoplasms",
        "Platinum-resistant Ovarian Cancer",
        "Platinum-refractory Ovarian Carcinoma",
        "CCNE1 Amplification",
        "Hormone Receptor Negative Breast Carcinoma",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "Progesterone-receptor-positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "NKT3447",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NiKang Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2024-02-23",
      "completion_date": "2025-04-16",
      "has_results": false,
      "last_update_posted_date": "2025-09-25",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Denver, Colorado • Celebration, Florida + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06264921"
    },
    {
      "nct_id": "NCT00193076",
      "title": "Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 96,
      "start_date": "2003-11",
      "completion_date": "2008-10",
      "has_results": false,
      "last_update_posted_date": "2011-05-03",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00193076"
    },
    {
      "nct_id": "NCT03646617",
      "title": "Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Radiation Therapy (HFRT)",
          "type": "RADIATION"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2018-11-27",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 3,
      "location_summary": "Lancaster, Pennsylvania • Philadelphia, Pennsylvania • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03646617"
    },
    {
      "nct_id": "NCT02570308",
      "title": "A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "IMCgp100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunocore Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2016-02-29",
      "completion_date": "2022-10-17",
      "has_results": true,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02570308"
    },
    {
      "nct_id": "NCT07182149",
      "title": "A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HNSCC",
        "ESCC",
        "Esophageal Adenocarcinoma",
        "Gastric Adenocarcinoma",
        "GEJ Adenocarcinoma",
        "Ovarian Cancer",
        "NSCLC",
        "Cervical Cancer",
        "Endometrial Cancer",
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "NRM-823",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Normunity AccelCo, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2025-10-30",
      "completion_date": "2028-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 18,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 13 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07182149"
    },
    {
      "nct_id": "NCT04208958",
      "title": "Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Melanoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "VE800",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin Oral Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Vedanta Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2020-01-23",
      "completion_date": "2023-02-23",
      "has_results": true,
      "last_update_posted_date": "2025-10-27",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 18,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04208958"
    },
    {
      "nct_id": "NCT02697591",
      "title": "A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignancies",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INCAGN01876",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Biosciences International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2016-06-20",
      "completion_date": "2019-12-16",
      "has_results": true,
      "last_update_posted_date": "2021-02-26",
      "last_synced_at": "2026-11-15T13:24:43.485Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02697591"
    }
  ]
}